製品の概要

  • 製品名
    Olomoucine
  • 製品の詳細
    ATP-competitive CDK inhibitor
  • 生理活性の詳細
    ATP-competitive CDK inhibitor (IC50 values are 7 (CDC2/cyclin B), 7 (CDK2/cyclin A), 7 (CDK2/cyclin E), 3 (CDK/p35 kinase) and 25 μM (ERK1/p44 MAPK)). Inhibits cell cycle progression in vitro and in vivo.
  • 精製度
    > 98%

製品の特性

参考文献

This product has been referenced in:
  • Zhu Z  et al. Inhibiting cell cycle progression reduces reactive astrogliosis initiated by scratch injury in vitro and by cerebral ischemia in vivo. Glia 55:546-58 (2007). Read more (PubMed: 17243097) »
  • Raynaud FI  et al. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Clin Cancer Res 11:4875-87 (2005). Read more (PubMed: 16000586) »
  • Veselý J  et al. Inhibition of cyclin-dependent kinases by purine analogues. Eur J Biochem 224:771-86 (1994). Read more (PubMed: 7925396) »

See 0 Publications for this product

レビューと Q&A

There are currently no Customer reviews or Questions for ab120938.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE, NOT FOR USE IN HUMANS"

登録